{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:18:33Z","timestamp":1793981913708,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100022","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T18:06:56Z","timestamp":1718042816000},"page":"100022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Mavani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2024.100022_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100022_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2024.100022_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100022_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.bneo.2024.100022_bib5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2024.100022_bib6","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1002\/hem3.74","article-title":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis","volume":"8","author":"Ghia","year":"2024","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.bneo.2024.100022_bib9","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bneo.2024.100022_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/cancers15020507","article-title":"Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for \u22655 years in the RESONATE-2 study","volume":"15","author":"Woyach","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bneo.2024.100022_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Skanland","year":"2021","journal-title":"Blood Adv"},{"issue":"16 suppl","key":"10.1016\/j.bneo.2024.100022_bib12","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1200\/JCO.2023.41.16_suppl.7538","article-title":"Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials","volume":"41","author":"Stephens","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2024.100022_bib13","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib14","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A\u00a0retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100022_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bneo.2024.100022_bib16","first-page":"1","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from Large Real-World Cohorts","author":"Martin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100022_bib17","first-page":"236","article-title":"Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib","volume":"23","author":"Chen","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.bneo.2024.100022_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cpt.2453","article-title":"The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: methodological recommendations from Oncology Case Studies","volume":"111","author":"Rivera","year":"2022","journal-title":"Clin Pharm Therap"},{"key":"10.1016\/j.bneo.2024.100022_bib19","first-page":"716","article-title":"Validation of real-world data-based endpoint measures of cancer treatment outcomes","volume":"2021","author":"Li","year":"2021","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.bneo.2024.100022_bib20","series-title":"Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)","author":"Rogers","year":"2023"},{"issue":"suppl","key":"10.1016\/j.bneo.2024.100022_bib21","article-title":"P621: real-world dosing patterns and time to next treatment for previously untreated patients with CLL\/SLL with or without ibrutinib dose reduction following an adverse event","volume":"7","author":"Shadman","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.bneo.2024.100022_bib22","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/j.clml.2022.07.004","article-title":"Real-world persistence and time to next treatment with ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma including patients at high risk for atrial fibrillation or stroke","author":"Narezkina","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib23","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1080\/03007995.2020.1835851","article-title":"Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia","volume":"36","author":"Huang","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.bneo.2024.100022_bib24","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.bneo.2024.100022_bib25","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","article-title":"A\u00a0pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib26","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100022_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oncolo\/oyac260","article-title":"Managing ibrutinib-intolerant patients with B-cell malignancies","volume":"28","author":"Munoz","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.bneo.2024.100022_bib28","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice","volume":"11","author":"O'Brien","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib29","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100022_bib30","series-title":"Prescribing information","year":"2022"},{"issue":"10","key":"10.1016\/j.bneo.2024.100022_bib31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100022_bib32","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2021-148155","article-title":"Majic: a phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2024.100022_bib33","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bneo.2024.100022_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100022_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bneo.2024.100022_bib36","series-title":"Causal Inference: What If","article-title":"Target trial emulation","author":"Hern\u00e1n","year":"2020"},{"issue":"5","key":"10.1016\/j.bneo.2024.100022_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.bneo.2024.100022_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1742-7843.2006.pto_329.x","article-title":"Comparison of dynamic treatment regimes via inverse probability weighting","volume":"98","author":"Hern\u00e1n","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"S2","key":"10.1016\/j.bneo.2024.100022_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pds.3253","article-title":"Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes","volume":"21","author":"Neugebauer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780091214","article-title":"Relation of pooled logistic regression to time dependent cox regression analysis: the Framingham heart study","volume":"9","author":"D'Agostino","year":"1990","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.bneo.2024.100022_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100022_bib42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2024.100022_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.bneo.2024.100022_bib44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100022_bib45","doi-asserted-by":"crossref","DOI":"10.2217\/ijh-2020-0010","article-title":"Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia","volume":"9","author":"Molica","year":"2020","journal-title":"International Journal of Hematologic Oncology"},{"issue":"8","key":"10.1016\/j.bneo.2024.100022_bib46","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/03007995.2021.1929894","article-title":"Real-world treatment sequencing and healthcare costs among CLL\/SLL patients treated with venetoclax","volume":"37","author":"Rogers","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.1016\/j.bneo.2024.100022_bib47","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100022_bib48","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.bneo.2024.100022_bib49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100022_bib50","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/PPA.S417180","article-title":"Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia","volume":"17","author":"Lu","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"20","key":"10.1016\/j.bneo.2024.100022_bib51","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2024.100022_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.898359","article-title":"Interventions to prevent potentially avoidable hospitalizations: a mixed methods systematic review","volume":"10","author":"Lyhne","year":"2022","journal-title":"Front Public Health"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100022_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-141650","article-title":"Study of low dose ibrutinib use in a community-based oncology practice","volume":"136","author":"Sanyal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100022_bib54","series-title":"CALQUENCE (acalabrutinib). Prescribing information","year":"2022"},{"key":"10.1016\/j.bneo.2024.100022_bib55","series-title":"BRUKINSA (zanubrutinib). Prescribing information","year":"2023"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:30:20Z","timestamp":1755999020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000220"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100022","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL\/SLL: a real-world analysis using target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100022"}}